Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Coronavirus Disease 2019 (COVID-19) Age: greater than 12 years Condition: Hospitalized, not requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) |
Dose: Injection – 200 mg intravenous loading dose on Day 1, then 100 mg intravenous maintenance dose Frequency: once daily Duration: 5 days; if clinical improvement not demonstrated, treatment may be extended up to 10 days total Note: Loading dose infused over 30-120 minutes. Hepatic impairment not evaluated; unknown if dosage adjustment required. Use only if potential benefit outweighs risk. |
|
Indication: Coronavirus Disease 2019 (COVID-19) Age: greater than 12 years Condition: Hospitalized, requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) |
Dose: Injection – 200 mg intravenous loading dose on Day 1, then 100 mg intravenous maintenance dose Frequency: once daily Duration: 10 days Note: Loading dose infused over 30-120 minutes. Hepatic impairment not evaluated; unknown if dosage adjustment required. Use only if potential benefit outweighs risk. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: COVID-19 Age: Pediatric Condition: Hospitalized |
Dose: Injection, lyophilized powder for reconstitution – 5 mg/kg Frequency: intravenous infused over 30-120 minutes loading dose on Day 1 Note: Use lyophilized powder to prepare dose for children aged less than 12 years or weight less than 40 kg according to Emergency Use Authorization |
|
Indication: COVID-19 Age: Pediatric Condition: Hospitalized |
Dose: Injection, lyophilized powder for reconstitution – 2.5 mg/kg Frequency: intravenous once daily starting Day 2 and thereafter Note: Use lyophilized powder to prepare dose for children aged less than 12 years or weight less than 40 kg according to Emergency Use Authorization |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment with eGFR greater than 30 mL/min |
Dose: Not specified Note: No dose adjustment |
|
Condition: Renal impairment with eGFR less than 30 mL/min |
Dose: Not specified Note: Not recommended unless the potential benefit outweighs potential risk; Pharmacokinetics have not been evaluated in patients with renal impairment; Use in patients with renal impairment are based on potential risk and potential benefit considerations |
Administration
- Must be administered by healthcare professionals
- Given as IV infusion over 30-120 minutes
Side Effect
- eGFR decreased* (18%)
- Decreased CrCl (calculated by Cockcroft-Gault) (10-18%)
- Creatinine increased (5-15%)
- Hemoglobin decreased (6-15%)
- Glucose increased (11-12%)
- Lymphocytes decreased (11%)
- Prothrombin time increased (9%)
- ALT increased (3-8%)
- AST increased (6-7%)
- Nausea (3-5%)
- Bilirubin increased (2%)
- Hypersensitivity reactions (Less than 2%)
- Generalized seizure (Less than 2%)
- Rash (Less than 2%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Chloroquine, hydroxychloroquine
|
Not recommended: may decrease antiviral activity
|
|
Strong CYP3A4 inducers
|
May decrease remdesivir levels
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Please do not reuse or save unused Remdesivir Lyophilized powder, injection solution or diluted solution for infusion for further use. This product contains no preservatives.
Lyophilized Powder: Please store Remdesivir for injection, 100 mg, vials at temperature not exceeding 30°C in a dry place until required for use. Protect from light & moisture. Do not use after expiration date.
After reconstitution: vials can be stored up to 4 hours at room temperature (20°C-25°C) prior to administration or 24 hours at refrigerated temperature (2°C-8°C). Please dilute within the same day as administration.
Diluted Solution for Infusion: Please store diluted Remdesivir solution for infusion up to 4 hours at room temperature (20°C-25°C) or 24 hours at refrigerated temperature (2°C-8°C).
Lyophilized Powder: Please store Remdesivir for injection, 100 mg, vials at temperature not exceeding 30°C in a dry place until required for use. Protect from light & moisture. Do not use after expiration date.
After reconstitution: vials can be stored up to 4 hours at room temperature (20°C-25°C) prior to administration or 24 hours at refrigerated temperature (2°C-8°C). Please dilute within the same day as administration.
Diluted Solution for Infusion: Please store diluted Remdesivir solution for infusion up to 4 hours at room temperature (20°C-25°C) or 24 hours at refrigerated temperature (2°C-8°C).
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.